https://www.selleckchem.com/products/ABT-888.html
3 (4.2) vs 13.2 (3.4); MMSE 14.3 (3.7) vs 12.2 (3.2), P0.05 respectively for each comparison). However, a statistical difference in terms of clinical benefit was similar between both the treatment groups (p0.05). Overall, both the study drugs were found comparable in relieving the symptoms of AD (severity score after end of treatment 14.2 vs 13.4 respectively; p 0.05). This indicates that MAO-B inhibitor is a potential target for the treatment of AD in China. The results of the present study may help to design a large clinic
Like
Comment
Share
